For ANXA5, STAT1, CD44, CAV1, and ANXA2, LGG patients with high expression possessed a worse overall survival, while low expression of MAPT was associated with poor overall survival among patients with primary gliomas. The gene discussed is STAT1; the disease is central nervous system cancer.